Reuters logo
1 个月前
BRIEF-Biomarin Pharmaceutical says plans to initiate phase 3 registrational study in Q4 2017 for BMN 270
2017年7月11日 / 早上8点04分 / 1 个月前

BRIEF-Biomarin Pharmaceutical says plans to initiate phase 3 registrational study in Q4 2017 for BMN 270

July 11 (Reuters) - Biomarin Pharmaceutical Inc

* Biomarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg dose maintains average factor VIII levels within normal range for over one year

* Biomarin Pharmaceutical Inc says plans to initiate a phase 3 registrational study in Q4 2017 for BMN 270 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below